Swiss National Bank Sells 1,300 Shares of Zoetis Inc. (NYSE:ZTS)

Swiss National Bank reduced its position in Zoetis Inc. (NYSE:ZTS) by 0.1% in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 1,354,332 shares of the company’s stock after selling 1,300 shares during the quarter. Swiss National Bank owned approximately 0.30% of Zoetis worth $264,609,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. First Personal Financial Services bought a new position in Zoetis in the third quarter worth $33,000. Capital Performance Advisors LLP bought a new position in Zoetis in the third quarter worth $33,000. Quarry LP lifted its position in Zoetis by 273.2% in the second quarter. Quarry LP now owns 209 shares of the company’s stock worth $36,000 after purchasing an additional 153 shares during the period. LRI Investments LLC bought a new position in Zoetis in the first quarter worth $43,000. Finally, Fortitude Family Office LLC lifted its position in Zoetis by 1,387.5% in the third quarter. Fortitude Family Office LLC now owns 238 shares of the company’s stock worth $46,000 after purchasing an additional 222 shares during the period. 92.80% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

ZTS has been the subject of several recent analyst reports. Piper Sandler increased their price objective on Zoetis from $195.00 to $210.00 and gave the stock an “overweight” rating in a research note on Wednesday, August 14th. BTIG Research increased their price objective on Zoetis from $220.00 to $225.00 and gave the stock a “buy” rating in a research note on Monday, August 12th. Argus upgraded Zoetis to a “strong-buy” rating in a research note on Friday, August 9th. JPMorgan Chase & Co. increased their price objective on Zoetis from $225.00 to $230.00 and gave the stock an “overweight” rating in a research note on Friday, October 11th. Finally, Stifel Nicolaus increased their price objective on Zoetis from $200.00 to $210.00 and gave the stock a “buy” rating in a research note on Wednesday, September 18th. Ten investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, Zoetis has an average rating of “Buy” and an average price target of $221.44.

Zoetis Stock Performance

Shares of NYSE:ZTS opened at $175.14 on Friday. Zoetis Inc. has a twelve month low of $144.80 and a twelve month high of $201.92. The firm has a market cap of $79.02 billion, a PE ratio of 32.92, a price-to-earnings-growth ratio of 2.69 and a beta of 0.90. The company has a debt-to-equity ratio of 1.26, a quick ratio of 2.27 and a current ratio of 3.69. The business has a fifty day moving average of $187.09 and a 200-day moving average of $180.23.

Zoetis (NYSE:ZTS) last posted its quarterly earnings results on Monday, November 4th. The company reported $1.58 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.46 by $0.12. The business had revenue of $2.40 billion for the quarter, compared to analysts’ expectations of $2.29 billion. Zoetis had a return on equity of 51.98% and a net margin of 26.55%. The firm’s quarterly revenue was up 11.6% compared to the same quarter last year. During the same quarter last year, the business earned $1.36 earnings per share. On average, equities research analysts predict that Zoetis Inc. will post 5.9 EPS for the current fiscal year.

Zoetis Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Tuesday, December 3rd. Investors of record on Thursday, October 31st will be issued a $0.432 dividend. This represents a $1.73 annualized dividend and a yield of 0.99%. The ex-dividend date of this dividend is Thursday, October 31st. Zoetis’s dividend payout ratio is 32.52%.

Zoetis Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.